GHRP-2 vs GHRP-6

Side-by-side comparison of GHRP-2, GHRP-6 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute GHRP-2 Growth Hormone Releasing Peptide-2 Growth Hormone GHRP-6 Growth Hormone Releasing Peptide-6 Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 66
Molecular weight 817.9 Da873.0 Da
Half-life ~1–2 hours~15–60 min
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular, Intranasal
Mechanism & Research
Primary mechanism GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH se… GHRP-6 activates ghrelin receptors (GHSR-1a) in both the hypothalamus and pituitary. Hypothalamic activation reduces somatostatin release (enabling larger GH pulses) and strongly activates appetite pathways — explaining …
Research status Research Compound Research Compound
Evidence summary GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class. GHRP-6 was one of the earliest compounds to enter GHRP clinical research, with human trials dating to the early 1990s. It has been used as a reference compound for characterising GHRP biology and ghrelin receptor pharmac…
Protocol & Dosing
Typical dose 100–200 mcg per injection100–300 mcg per injection
Frequency 2–3x daily2–3× daily
Duration 8–12 weeks8–12 weeks
Timing Fasted state; 2+ hours post-mealFasted state or 2+ hours post-meal
Safety
Common side effects
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Increased appetite
  • Water retention
  • Significant appetite increase (most common)
  • Cortisol elevation (dose-dependent)
  • Prolactin increase (transient)
  • Water retention
Contraindications
  • Active malignancy
  • Hypothyroidism
  • Pregnancy
  • Active malignancy
  • Eating disorders (appetite amplification concern)
  • Hypothyroidism
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides Ipamorelin, CJC-1295, GHRP-6, Hexarelin Ipamorelin, GHRP-2, Hexarelin, CJC-1295
Full profile Read full GHRP-2 profile → Read full GHRP-6 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.